Overview

• The Journal of Nuclear Medicine published peer-reviewed research identifying HER2 and CD24 as leading candidates for imaging and targeted therapy in endometrial cancer.
• Researchers compared antigen expression of HER2, MUC16, and CD24 in cancer cell lines and patient tissues against healthy controls.
• Three 89Zr-labeled immunoPET probes were tested in murine models: 89Zr-DFO-trastuzumab (HER2), 89Zr-DFO-AR9.6 (MUC16), and 89Zr-DFO-ATG-031 (CD24).
• CD24-targeted 89Zr-DFO-ATG-031 achieved the highest tumor uptake and contrast, HER2 imaging showed moderate promise, and MUC16 imaging performed poorly.
• Findings were reinforced in patient-derived xenograft models, with authors emphasizing the need for safety, dosimetry, and human imaging trials before clinical use.